OLVIG
BCRX icon

Oliver Lagore Vanvalin Investment Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Oliver Lagore Vanvalin Investment Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,180
Closed -$7.29K – 693
2024
Q2 		$7.29K Buy
+1,180
New +$6.51K ﹤0.01% 454

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Oliver Lagore Vanvalin Investment Group's BCRX Position: Q3 2024 in Review

Oliver Lagore Vanvalin Investment Group sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2024, closing a stake of 1,180 shares — an estimated $7.29K sold.

Oliver Lagore Vanvalin Investment Group first reported a position in BCRX in Q2 2024 and held it in 1 quarter. The position peaked at $7.29K in Q2 2024. 257 funds tracked by Wall St. Rank hold BCRX as of Q3 2024.

  • Oliver Lagore Vanvalin Investment Group reported no remaining BioCryst Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Oliver Lagore Vanvalin Investment Group sold 1,180 BioCryst Pharmaceuticals shares in Q3 2024, an estimated $7.29K.
  • Oliver Lagore Vanvalin Investment Group first reported a position in BioCryst Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Oliver Lagore Vanvalin Investment Group's BioCryst Pharmaceuticals position peaked at $7.29K in Q2 2024.
  • 257 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2024.

Based on Oliver Lagore Vanvalin Investment Group's 13F filing for Q3 2024, filed 4 Nov 2024.